智通财经APP讯，华润医药(03320)发布截至2026年6月30日止六个月业绩，收益1344.576亿元，同比增长2%;公司权益股东应占溢利21.87亿元，同比增长5.3%;每股基本盈利0.35元，拟派中期股息每股0.087元。
2026年上半年制药、医药分销、药品零售及其他三个主要业务分部的收益占比分别为16.2%、79.1%以及4.7%。
报告期内，集团制药业务实现分部收益244.447亿元，同比略降1.5%。制药业务毛利率为60.3%，较上年同期上升1.0个百分点。
报告期内，集团医药分销业务实现分部收益1109.948亿元，同比增长2.5%。分销业务毛利率为5.7%，较上年同期微降0.2个百分点。
报告期内，集团医药零售业务取得收益63.372亿元，同比增长14.9%。其中，高值药品直送(DTP)业务实现收益约48.3亿元，同比增长28.6%。零售业务毛利率为6.3%，较上年同期提升0.2个百分点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.